Egrifta

Product Name: Egrifta
CAS No.: 804475-66-9
Chemical Name: Egrifta
Synonyms: Th-9507;Th 9507;Egrifta;Tesamerelin;Unii-mqg94m5eeo;High Pure Peptides Th9507 Tesamorelin Powder 2mg/Vial
CBNumber: CB52493342
Molecular Formula: C221H366N72O67S
Formula Weight: 5135.77794
MOL File: 804475-66-9.mol

More

Less

Egrifta Property

InChI: InChI=1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1
InChIKey: QBEPNUQJQWDYKU-BMGKTWPMSA-N
SMILES: S(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C(N([H])[C@@]([H])(C([H])([H])O[H])C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])C([H])([H])C(N([H])[C@]([H])(C(N([H])[C@@]([H])(C([H])([H])O[H])C(N([H])[C@@]([H])(C([H])([H])C(N([H])[H])=O)C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])C([H])([H])C(N([H])[C@@]([H])(C([H])([H])[H])C(N([H])[C@]([H])(C(N([H])[C@@]([H])(C([H])([H])[H])C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])=O)=O)=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])=O)C([H])([H])C([H])([H])C(=O)O[H])=O)C([H])([H])C([H])([H])C(N([H])[H])=O)=O)=O)=O)C([H])([H])C([H])([H])C(=O)O[H])=O)=O)C([H])([H])C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])=O)=O)N([H])C([C@]([H])([C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C(=O)O[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C(N([H])[H])=O)N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])O[H])N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C(N([H])[H])=O)N([H])C(C([H])([H])N([H])C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])C([C@]([H])(C([H])([H])O[H])N([H])C([C@]([H])(C([H])([H])C(N([H])[H])=O)N([H])C([C@]([H])([C@@]([H])(C([H])([H])[H])O[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C([C@]([H])([C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C(=O)O[H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])C(C([H])([H])/C(/[H])=C(\[H])/C([H])([H])C([H])([H])[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Egrifta Chemical Properties,Usage,Production

Description

Tesamorelin acetate is an analog of growth hormone-releasing hormone (GHRH) that was approved in the United States in 2010 for treatment of lipodystrophy in HIV patients. Tesomorelin is an analog of GHRH. GHRH stimulates the synthesis and release of GH. In the pituitary, GH is secreted in a pulsatile manner. GH control is regulated by somatostatin and the negative feedback regulator, IGF-1. Direct administration of GH to patients with lipodystrophy decreases VAT but has associated side effects such as fluid retention and joint swelling. Because of the side effects associated with direct GH administration, GHRH represents a attractive mechanism for increasing GH levels. Tesomorelin is an analog of GHRH in which the N-terminal amino acid, Tyr, is amidated with a trans-3-hexenoyl group. Capping of the N-terminus protects GHRH from cleavage by DPP-4. Tesomorelin demonstrates enhanced stability compared with GHRH in animal models.

Originator

Theratechnologies (Canada)

Uses

Egrifta (Tesamorelin) is used to reduce excess abdominal fat in HIV-infected lipodystrophy patients. Some HIV medicines cause this side effect (increased fat in the upper back and abdomen and decreased fat in the arms and legs.) Tesamorelin works by making the body produce more growth hormone. This medicine should not be used for weight loss.

brand name

Egrifta

Biological Activity

Egrifta (Tesamorelin) is a synthetic growth hormone-releasing hormone analog and a GHRH agonist that stimulates the synthesis and release of endogenous growth hormone.

Side effects

Adverse reactions to Egrifta (Tesamorelin) include redness, itching, pain, irritation, or bruising at the injection site. Muscle soreness may also occur. In addition, muscle/joint pain or stiffness; numbness/tingling/swelling in the arms or legs; elevated blood sugar (increased thirst/urination), Rare adverse reactions include: very severe allergic reactions such as rash, itching/swelling (especially of the face/tongue/throat), dizziness, facial severity, difficulty breathing; and an increased risk of new cancers or recurrence of previous melanoma.

Egrifta Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Egrifta Suppliers

China 34 Global 34

Shenzhen Simeiquan Biotechnology Co. Ltd

Tel: 18126413629 0755-23311925 2355327053
Fax: 0755-23311925
Email: abel@ycgmp.com
Country: China
ProdList: 5113
Advantage: 58

Shenzhen Sendi Biological Technology Co., Ltd.

Tel: 18124570582 TEL：0755-23574479 2355327139
Fax: 0755-23229476 QQ: 2355327139
Email: siliao02@yccreate.com
Country: China
ProdList: 6116
Advantage: 58

Chengdu Youngshe Chemical Co., Ltd.

Tel: +86-17380623303 +86-17380623303
Fax: 028-62328193
Email: Caroline@youngshechem.com
Country: China
ProdList: 4814
Advantage: 58

Zhuhai JiaYi Biological Technology Co., Ltd.

Tel: 18578209868 2355327026
Fax: 18578209868 QQ：2355327026
Email: steroidbest@hotmail.com
Country: China
ProdList: 6501
Advantage: 58

Hebei Mojin Biotechnology Co., Ltd

Tel: +86 13288715578 +8613288715578
Email: sales@hbmojin.com
Country: China
ProdList: 12834
Advantage: 58

Wuhan Golt Biotech Co., Ltd.

Tel: +8615389281203
Email: maria@goltbiotech.com
Country: China
ProdList: 970
Advantage: 58

Hebei Qige Biological Technology Co. Ltd

Tel: +86 +8618733132031
Country: CHINA
ProdList: 1303
Advantage: 58

Qiuxian Baitai New Material Co., LTD

Tel: +8618330912755
Fax: +8619932103556
Email: sale2@hbyalin.com
Country: China
ProdList: 1658
Advantage: 58

Hebei Zhanyao Biotechnology Co. Ltd

Tel: 15369953316 +8615369953316
Email: admin@zhanyaobio.com
Country: China
ProdList: 2123
Advantage: 58

Shanghai Longyu Biotechnology Co., Ltd.

Tel: +8619521488211
Fax: +86 15821988213
Email: info@longyupharma.com
Country: China
ProdList: 2541
Advantage: 58

More

Less

View Lastest Price from Egrifta manufacturers

.GZ HONESTCHEM CO.,LTD

Product: Tesamorelin
Price: US $1.00/kit
Min. Order: 1kit
Purity: 99.9%
Supply Ability: 200
Release date: 2019-10-20

Wuhan Cell Pharmaceutical Co., Ltd

Product: Tesamorelin 804475-66-9
Price: US $9.90-9.90/mg
Min. Order: 1mg
Purity: 99%
Supply Ability: 1000g
Release date: 2023-03-31

zhuzhou dingcheng meihei comestic co.,ltd

Product: Tesamorelin 804475-66-9
Price: US $30.00/Box
Min. Order: 1Box
Purity: 99.99%
Supply Ability: 10000000000
Release date: 2023-12-05

804475-66-9, EgriftaRelated Search:

Th 9507

Th-9507

Unii-mqg94m5eeo

High Pure Peptides Th9507 Tesamorelin Powder 2mg/Vial

Tesamerelin

Egrifta

804475-66-9